Pr Francois DUCRAY

Full professor of neurology, president of the ANOCEF, François Ducray’s clinical activity is dedicated to brain tumor patients. He leads several national and international clinical trials and a research group at the Cancer Research Center of Lyon. His research activity is focused on multi-omic characterization of adult gliomas (glioblastomas, IDH-mutated gliomas) and development of new pre-clinical models of gliomas in close collaboration with the French POLA network.

1. First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: Case report and illustrative review

De Rosa A, Calvanese F, Ducray F, Vasiljevic A, Manet R, Raverot G, Jouanneau E

Ann Endocrinol (Paris). 2023

2. Use of 5-ALA fluorescence-guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study

Picart T, Pallud J, Berthiller J, Dumot C, Berhouma M, Ducray F, Armoiry X, Margier J, Guerre P, Varlet P, Meyronet D, Metellus P, Guyotat J; Members of RESECT study group

J Neurosurg. 2023

3. Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations

Roberts HJ, Ji S, Picca A, Sanson M, Garcia M, Snuderl M, Schüller U, Picart T, Ducray F, Green AL, Nakano Y, Sturm D, Abdullaev Z, Aldape K, Dang D, Kumar-Sinha C, Wu YM, Robinson D, Vo JN, Chinnaiyan AM, Cartaxo R, Upadhyaya SA, Mody R, Chiang J, Baker S, Solomon D, Venneti S, Pratt D, Waszak SM, Koschmann C

Acta Neuropathol. 2023

4. Pituitary Tumor Centers of Excellence (PTCOE) should now include neuro-oncologic input

Jouanneau E, Calvanese F, Ducray F, Raverot G

Pituitary. 2023

5. Nocardia brain abscess mimicking tumor progression in an elderly glioblastoma patient treated with temozolomide radiochemotherapy

Kourouma M, Joubert B, Berhouma M, Roux S, Meyronet D, Ducray F

Rev Neurol (Paris). 2023

6. Pseudocystic inflammatory demyelinating lesions in multiple sclerosis: A clinical, radiological, and pathological description

Cluse F, Fenouil T, Vukusic S, Ducray F, Cotton F, Marignier R, Durand-Dubief F

Mult Scler. 2023

7. Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2’O-methylation of ribosomal RNA

Paraqindes H, Mourksi NE, Ballesta S, Hedjam J, Bourdelais F, Fenouil T, Picart T, Catez F, Combe T, Ferrari A, Kielbassa J, Thomas E, Tonon L, Viari A, Attignon V, Carrere M, Perrossier J, Giraud S, Vanbelle C, Gabut M, Bergeron D, Scott MS, Castro Vega L, Magne N, Huillard E, Sanson M, Meyronet D, Diaz JJ, Ducray F, Marcel V, Durand S

Neuro Oncol. 2023

8. A noncoding SNP at chromosome 8q24 is implicated in oncogenesis of IDH-mutant gliomas

Couderc-Enguiale I, Ducray F

Med Sci (Paris). 2023

9. A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas

Gilhodes J, Meola A, Cabarrou B, Peyraga G, Dehais C, Figarella-Branger D, Ducray F, Maurage CA, Loussouarn D, Uro-Coste E, Cohen-Jonathan Moyal E, Pola Network

Cancers (Basel). 2023

10. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, Chinot O, Ducray F, Roth P, McDonald K, Hau P, Hottinger AF, Reijneveld J, Schnell O, Marosi C, Glantz M, Darlix A, Lombardi G, Krex D, Glas M, Reardon DA, van den Bent M, Lefranc F, Herrlinger U, Razis E, Carpentier AF, Phillips S, Rudà R, Wick A, Tabouret E, Meyronet D, Maurage CA, Rushing E, Rapkins R, Bumes E, Hegi M, Weyerbrock A, Aregawi D, Gonzalez-Gomez C, Pellerino A, Klein M, Preusser M, Bendszus M, Golfinopoulos V, von Deimling A, Gorlia T, Wen PY, Reifenberger G, Weller M.

Eur J Cancer. 2023